NF-Kappa B Inhibitors Clinical Pipeline Research Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “NF-Kappa B Inhibitors – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.

This “NF-kappa B Inhibitors – Pipeline Insight, 2021” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in NF-kappa B Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

NF-kappa B Inhibitors Emerging Drugs Chapters

This segment of the NF-kappa B Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

NF-kappa B Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different NF-kappa B Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on NF-kappa B Inhibitors

There are approx. 10+ key companies which are developing the NF-kappa B Inhibitors. The companies which have their NF-kappa B Inhibitors drug candidates in the most advanced stage, i.e. phase III include, Merck.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

NF-kappa B Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

• Topical
• Oral
• Intravenous
• Parenteral
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Gene Therapies
• Peptides
• Oligonucleotides
• Small molecule
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

NF-kappa B Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses NF-kappa B Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NF-kappa B Inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence NF-kappa B Inhibitors R&D. The therapies under development are focused on novel approaches for NF-kappa B Inhibitors.

NF-kappa B Inhibitors Report Insights

• NF-kappa B Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

NF-kappa B Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Scenario and Emerging Therapies:

• How many companies are developing NF-kappa B Inhibitors drugs?
• How many NF-kappa B Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for NF-kappa B Inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the NF-kappa B Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for NF-kappa B Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck
• NeurMedix
• AnGes
• Complexa
• GeneOne Life Science
• Accendatech
• Link Health Group
• Immix Biopharma
• First Wave Bio
• IMMD
• ILIAS Biologics

Key Products

• MK-7110
• NE3107
• AMG 0101
• CXA-10
• GLS-1027
• ACT001
• LH-025
• IMX-110
• FW 424
• IMD-2560
• ILB-202

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/xezh3o

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900